Delivery Order SPE2DR25D9168-SPE2DR26FCSF9
Award Date 3/18/26
Potential Completion Date 4/8/26
Potential Value $4.1K
Federal Agency
Ultimate Awardee
Not listed PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Park Ridge, IL 60068, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The Defense Logistics Agency issued a delivery order to DMS Pharmaceutical Group Inc. on March 10, 2026, for Ozurdex 0.7 mg implants with a ceiling value of $3,076.23, issued under the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V). PPV-G GEN V is a Defense Logistics Agency indefinite delivery contract supporting pharmaceutical and medical consumable supply to Department of Defense healthcare facilities worldwide. The contract was awarded to DMS Pharmaceutical Group on...
- The Defense Logistics Agency issued a delivery order to DMS Pharmaceutical Group Inc. on March 2, 2026, for Ozurdex 0.7 mg implants, with a ceiling value of $2,050.84. DMS Pharmaceutical Group Inc. is a woman-owned small business pharmaceutical wholesaler. This delivery order is issued under the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V), a single-award indefinite delivery contract with a $499.999 billion ceiling and ultimate completion...
- The Defense Logistics Agency issued a delivery order to DMS Pharmaceutical Group Inc. on March 13, 2026, for $10,254.10 in OZURDEX 0.7 mg implants, with an ultimate completion date of April 3, 2026. The order is issued under the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V), the Defense Logistics Agency's single-award indefinite delivery contract authorizing firm fixed-price delivery orders for pharmaceuticals and medical consumables to support Department of Defense...
- The Defense Logistics Agency issued a $5,127.05 delivery order to DMS Pharmaceutical Group Inc. on March 6, 2026, for OZURDEX 0.7 mg implants under its Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) indefinite delivery contract. DMS Pharmaceutical Group Inc. is a woman-owned small business pharmaceutical wholesaler. Place of performance is Park Ridge, IL. The order has a firm fixed price and an ultimate completion date of March 27, 2026. The parent PPV-G GEN V contract,...
- The Defense Logistics Agency awarded a $4,101.68 firm fixed-price delivery order to DMS Pharmaceutical Group Inc. for OZURDEX 0.7 mg implants, effective January 21, 2026, with an ultimate completion date of February 11, 2026. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, was selected without a set-aside designation, demonstrating the company's competitive capability in unrestricted federal procurement. The delivery...
- The Defense Logistics Agency awarded a delivery order valued at $3,016.14 to DMS Pharmaceutical Group Inc. on September 10, 2025, for the supply of Ozurdex 0.7 mg implants. This firm fixed-price delivery order, which carries an ultimate completion date of October 1, 2025, is issued under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with the DLA under the SPE2DB program. The delivery order does not utilize a set-aside designation and will be performed at the contractor's...
- The U.S. Defense Logistics Agency Troop Support Medical has awarded a firm fixed-price delivery order contract to DMS Pharmaceutical Group Inc., a woman-owned small business based in Park Ridge, Illinois. The contract, valued at $3,004.53, is for the delivery of OZURDEX 0.7 MG IMPLANTS with a completion date of March 12, 2024. DMS Pharmaceutical Group Inc. holds a larger indefinite delivery contract, contract 4600082013 under the SPE2DB program, valued at up to $4,999,999 through the end of 2025...
- The U.S. Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $2,003.02 contract is for the supply of Ozurdex 0.7 mg implants, a specialized pharmaceutical product. This delivery order is part of a larger $499,999,999 indefinite delivery contract (IDC) held by DMS Pharmaceutical Group with the DLA under the SPE2DB program. The IDC allows the DLA...
- The U.S. Defense Logistics Agency (DLA) awarded a firm-fixed-price delivery order contract valued at $4,006.04 to DMS Pharmaceutical Group Inc., a woman-owned small business, for the supply of OZURDEX 0.7 MG IMPLANTS. This order was placed under DMS Pharmaceutical Group's larger indefinite delivery contract (IDC) with the DLA, valued at up to $499,999,999, to provide a comprehensive range of pharmaceutical items in support of military health facilities worldwide. The contract has a period of...
- This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract, valued at $3,004.53, is for the delivery of OZURDEX 0.7 MG IMPLANTS to support the recurring pharmaceutical supply needs of military health facilities. DMS Pharmaceutical Group holds a larger Indefinite Delivery Contract (IDC) with the DLA, valued at up to...